Abstract:The novelty of new human coronavirus COVID-19/SARS-CoV-2 and the lack of effective drugs and vaccines gave rise to a wide variety of strategies employed to fight this worldwide pandemic. Many of these strategies rely on the repositioning of existing drugs that could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we presented a new network-based algorithm for drug repositioning, called SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), which predicts drug–disease associations by quantifying the interplay between the drug targets and the disease-specific proteins in the human interactome via a novel network-based similarity measure that prioritizes associations between drugs and diseases locating in the same network neighborhoods. Specifically, we applied SAveRUNNER on a panel of 14 selected diseases with a consolidated knowledge about their disease-causing genes and that have been found to be related to COVID-19 for genetic similarity (i.e., SARS), comorbidity (e.g., cardiovascular diseases), or for their association to drugs tentatively repurposed to treat COVID-19 (e.g., malaria, HIV, rheumatoid arthritis). Focusing specifically on SARS subnetwork, we identified 282 repurposable drugs, including some the most rumored off-label drugs for COVID-19 treatments (e.g., chloroquine , hydroxychloroquine , tocilizumab , heparin ), as well as a new combination therapy of 5 drugs ( hydroxychloroquine , chloroquine , lopinavir , ritonavir , remdesivir ), actually used in clinical practice. Furthermore, to maximize the efficiency of putative downstream validation experiments, we prioritized 24 potential anti-SARS-CoV repurposable drugs based on their network-based similarity values. These top-ranked drugs include ACE-inhibitors, monoclonal antibodies (e.g., anti-IFNγ, anti-TNFα, anti-IL12, anti-IL1β, anti-IL6), and thrombin inhibitors. Finally, our findings were in-silico validated by performing a gene set enrichment analysis, which confirmed that most of the network-predicted repurposable drugs may have a potential treatment effect against human coronavirus infections.

Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection

Machine-Learning Driven Drug Repurposing for COVID-19

Machine Learning Applications in Drug Repurposing

Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics

Deep learning for drug repurposing: Methods, databases, and applications

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

Repurposing drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2

Accelerating drug repurposing for COVID-19 treatment by modeling mechanisms of action using cell image features and machine learning

Drug repurposing prediction for COVID-19 using probabilistic networks and crowdsourced curation

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

An in silico drug repurposing pipeline to identify drugs with the potential to inhibit SARS-CoV-2 replication

Network analytics for drug repurposing in COVID-19

Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome

Accelerating drug repurposing for COVID-19 via modeling drug mechanism of action with large scale gene-expression profiles

In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches

A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism

SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19

Drug Repurposing For SARS-COV-2 Using Molecular Docking

In silico Drug Repurposing for COVID‐19: Targeting SARS‐CoV‐2 Proteins through Docking and Consensus Ranking